{"id":403753,"date":"2020-12-21T09:18:07","date_gmt":"2020-12-21T14:18:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403753"},"modified":"2020-12-21T09:18:07","modified_gmt":"2020-12-21T14:18:07","slug":"exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/","title":{"rendered":"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034<\/b><\/p>\n<p class=\"bwalignc\"><i>Patents and patent application provide additional coverage for company\u2019s therapeutic for patients with advanced solid tumors<\/i><\/p>\n<p>CHICAGO &amp; CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nExicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) constructs, today announced that the U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the \u2018251 patent) and No. 10,837,018 (the \u2018018 patent), and allowed U.S. patent application 14\/907,430 (the \u2018430 application), further strengthening the Company\u2019s intellectual property position and coverage for the Company\u2019s therapeutic product candidate, cavrotolimod.\n<\/p>\n<p>\nThe \u2018018 patent and the \u2018430 application, both titled, \u201cSpherical Nucleic Acid-based Constructs as Immunostimulatory Agents for Prophylactic and Therapeutic Use,\u201d covers nanoparticles with a corona of CpG oligonucleotides and their methods for treating cancer.\n<\/p>\n<p>\nThe \u2018251 patent, jointly owned by the Company and Northwestern University, titled, \u201cLiposomal Particles, Methods of Making Same and Uses Thereof,\u201d is directed to liposomal nanoparticles with toll-like receptor 9 (TLR9) agonist oligonucleotides and methods for treating cancer.\n<\/p>\n<p>\n\u201cThe two issued patents and the soon-to-be-issued patent demonstrate our commitment to developing cavrotolimod, which is currently in a Phase 2 clinical trial for the potential treatment of Merkel cell carcinoma and cutaneous squamous cell carcinoma,\u201d said David Giljohann, Chief Executive Officer of Exicure. \u201cWe are pleased with cavrotolimod\u2019s development to date and excited about its potential to address unmet need for patients living with these rare forms of skin cancers.\u201d\n<\/p>\n<p><b>About Exicure, Inc.<\/b><\/p>\n<p>\nExicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA\u2013based therapeutic candidate, for the treatment of Friedreich\u2019s ataxia (FA). Exicure&#8217;s drug candidate AST-008 is currently in a Phase 1b\/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.\n<\/p>\n<p>\nFor more information, visit Exicure\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exicuretx.com&amp;esheet=52352084&amp;newsitemid=20201221005412&amp;lan=en-US&amp;anchor=www.exicuretx.com&amp;index=1&amp;md5=8b40af6e0e7db4bcd29ea1c624dc5c4e\">www.exicuretx.com<\/a>.\n<\/p>\n<p><b>Exicure Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact could be deemed forward looking including, but not limited to, statements regarding the company\u2019s intellectual property portfolio. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update these forward-looking statements. Forward-looking statements are based on management\u2019s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risks that the ongoing COVID-19 pandemic may disrupt the company\u2019s business and\/or the global healthcare system more severely than it has to date or more severely than anticipated, which may have the effect of impacting or delaying the company\u2019s ongoing Phase 1b\/2 clinical trial; unexpected costs, charges or expenses that reduce the company\u2019s capital resources; the company\u2019s preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; risks that preliminary results from clinical trials are not necessarily predictive of future clinical trial results; and the ability of the company to protect its intellectual property rights. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company\u2019s actual results to differ from those contained in the forward-looking statements, see the section titled \u201cRisk Factors\u201d in the company\u2019s Quarterly Report on Form 10-Q, as updated by the company\u2019s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the company undertakes no duty to update this information, except as required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201221005412\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201221005412\/en\/<\/a><\/span><\/p>\n<p><b>For Media:<br \/>\n<\/b><br \/>Karen Sharma<br \/>\n<br \/>MacDougall<br \/>\n<br \/>781-235-3060<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ksharma@macbiocom.com\">ksharma@macbiocom.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Illinois Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201221005412\/en\/651600\/3\/Exicure_Logo_FINAL_Full_Color-072515.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 Patents and patent application provide additional coverage for company\u2019s therapeutic for patients with advanced solid tumors CHICAGO &amp; CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) constructs, today announced that the U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the \u2018251 patent) and No. 10,837,018 (the \u2018018 patent), and allowed U.S. patent application 14\/907,430 (the \u2018430 application), further strengthening the Company\u2019s intellectual property position and coverage for the Company\u2019s therapeutic product candidate, cavrotolimod. The \u2018018 patent and the \u2018430 application, both titled, \u201cSpherical Nucleic Acid-based Constructs as Immunostimulatory &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403753","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 Patents and patent application provide additional coverage for company\u2019s therapeutic for patients with advanced solid tumors CHICAGO &amp; CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) constructs, today announced that the U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the \u2018251 patent) and No. 10,837,018 (the \u2018018 patent), and allowed U.S. patent application 14\/907,430 (the \u2018430 application), further strengthening the Company\u2019s intellectual property position and coverage for the Company\u2019s therapeutic product candidate, cavrotolimod. The \u2018018 patent and the \u2018430 application, both titled, \u201cSpherical Nucleic Acid-based Constructs as Immunostimulatory &hellip; Continue reading &quot;Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T14:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034\",\"datePublished\":\"2020-12-21T14:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/\"},\"wordCount\":818,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/\",\"name\":\"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-21T14:18:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/","og_locale":"en_US","og_type":"article","og_title":"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 - Market Newsdesk","og_description":"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 Patents and patent application provide additional coverage for company\u2019s therapeutic for patients with advanced solid tumors CHICAGO &amp; CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) constructs, today announced that the U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the \u2018251 patent) and No. 10,837,018 (the \u2018018 patent), and allowed U.S. patent application 14\/907,430 (the \u2018430 application), further strengthening the Company\u2019s intellectual property position and coverage for the Company\u2019s therapeutic product candidate, cavrotolimod. The \u2018018 patent and the \u2018430 application, both titled, \u201cSpherical Nucleic Acid-based Constructs as Immunostimulatory &hellip; Continue reading \"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T14:18:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034","datePublished":"2020-12-21T14:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/"},"wordCount":818,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/","name":"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-21T14:18:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005412r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-announces-issuance-of-two-new-u-s-patents-and-a-new-patent-allowance-covering-cavrotolimod-through-2034\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403753"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403753\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}